Pfizer Inc. (PFE)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Albert Bourla D.V.M., Ph.D. | Chairman of the Board & CEO | 4.05M | -- | 1962 |
Mr. David M. Denton | Chief Financial Officer & Executive VP | 1.75M | -- | 1965 |
Dr. Mikael Dolsten M.D., Ph.D. | Chief Scientific Officer and President of Research & Development | 2.41M | -- | 1958 |
Mr. Douglas M. Lankler | Executive VP & General Counsel | 1.76M | -- | 1966 |
Mr. Aamir Malik | Executive VP & Chief U.S. Commercial Officer | 1.89M | -- | 1976 |
Ms. Jennifer B. Damico | Senior VP, Controller & Principal Accounting Officer | -- | -- | 1968 |
Ms. Lidia L. Fonseca | Executive VP and Chief Digital & Technology Officer | -- | -- | 1969 |
Ms. Francesca M. DeMartino | Chief Investor Relations Officer | -- | -- | -- |
Mr. Rady A. Johnson | Executive VP and Chief Compliance, Quality & Risk Officer | -- | -- | 1962 |
Mr. Andreas J. Panayiotou | Global Chief Marketing Officer | -- | -- | -- |
Pfizer Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 88,000
Description
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Corporate Governance
Recent Events
- Apr 11, 2024DEFA14A: Proxy StatementsSee Full Filing
- Apr 09, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 28, 2024DEFA14A: Proxy StatementsSee Full Filing
- Mar 22, 2024SC 13D/A: Tender Offer/Acquisition ReportsSee Full Filing
- Mar 19, 2024SC 13D/A: Tender Offer/Acquisition ReportsSee Full Filing
Upcoming Events
May 09, 2024
Ex-Dividend Date